MIM
INSY

MetLife Investment Management’s Insys Therapeutics, Inc. INSY Stock Holding History

MetLife Investment Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,114
Closed -$142K – 2627
2018
Q3 		$142K Buy
+14,114
New +$113K ﹤0.01% 2272

Other funds holding INSY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

MetLife Investment Management's INSY Position: Q4 2018 in Review

MetLife Investment Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 14,114 shares — an estimated $142K sold.

MetLife Investment Management first reported a position in INSY in Q3 2018 and held it in 1 quarter. The position peaked at $142K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • MetLife Investment Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • MetLife Investment Management sold 14,114 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $142K.
  • MetLife Investment Management first reported a position in Insys Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • MetLife Investment Management's Insys Therapeutics, Inc. position peaked at $142K in Q3 2018.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on MetLife Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.